Details of a Researcher - Okamura, Tomonori

Reviews, Commentaries, etc. - Okamura, Tomonori

Division display >> ／ All the affair displays 1 - 33 of about 33

The JSH Morning Hypertension Eradication Program Project

Kario K., Nishiyama A., Shibata S., Mogi M., Arima H., Kishi T., Ishida M., Furuhashi M., Ichihara A., Katsuya T., Miura K., Miura S.I., Ohishi M., Shibata H., Shimosawa T., Sugawara A., Tamura K., Toyoda K., Yamamoto K., Hoshide S., Nakagawa N., Tomita H., Tanaka A., Hozawa A., Hatta T., Nomura A., Kabayama M., Rakugi H., Ohya Y., Node K., Tomitani N., Asayama K., Ohkubo T., Sakima A., Hirawa N., Shinohara K., Kaneko H., Takemi Y., Okamura T., Kawarazaki W., Arakawa K., Kai H., Shimosawa T., Tomita H.

Hypertension Research 48 ( 11 ) 2771 - 2780 2025.11

ISSN 09169636

Hypertension is the greatest risk factor for cardiovascular diseases and significantly contributes to cardiovascular mortality. In Japan, the hypertensive population is estimated at 43 million, with only 27% achieving well-controlled blood pressure (BP). The onset of major cardiovascular events, including stroke, myocardial infarction, heart failure, and aortic dissection, frequently occurs during the early morning hours. Accordingly, for over 20 years, the Japanese Society of Hypertension (JSH) has prioritized the management of early morning hypertension and has emphasized the importance of antihypertensive treatment guided by home BP in its treatment guidelines. However, even among hypertensive patients with multiple medications, control of morning BP remains suboptimal, with fewer than 30% achieving target levels below 130/80 mmHg. To address this serious situation, JSH announced their Declaration for the Eradication of Morning Hypertension in 2025, in conjunction with the release of the Guidelines for the Management of Elevated Blood Pressure and Hypertension 2025. The primary specific measure of the declaration involves the Asakatsu BP Action Plan – the Morning Blood Pressure 130 Campaign – which encourages individuals to monitor their morning blood pressure (BP) in various settings, such as homes, workplaces, and BP kiosks set up in public spaces. Additionally, JSH is promoting a Systematic Review Project to raise awareness of the importance of early morning hypertension management nationally and internationally, and a Data Science Project to examine how digital technology can contribute to the promotion of personalized and anticipation medicine through “digital hypertension” research. (Figure presented.)

Access to Document (DOI)

Declaration for the eradication of morning hypertension

Kario K., Nishiyama A., Shibata S., Mogi M., Arima H., Kishi T., Ishida M., Furuhashi M., Ichihara A., Katsuya T., Miura K., Miura S.I., Node K., Ohishi M., Shibata H., Shimosawa T., Sugawara A., Tamura K., Toyoda K., Yamamoto K., Tomitani N., Asayama K., Ohkubo T., Rakugi H., Sakima A., Hirawa N., Ohya Y., Shinohara K., Kaneko H., Takemi Y., Okamura T., Kawarazaki W., Arakawa K., Kai H., Kabayama M., Nomura A., Hatta T., Hozawa A., Tanaka A., Tomita H., Nakagawa N., Hoshide S.

Hypertension Research 48 ( 9 ) 2287 - 2289 2025.09

ISSN 09169636

Access to Document (DOI)

Correction to: Universal health coverage in the context of population ageing: catastrophic health expenditure and unmet need for healthcare (Health Economics Review, (2024), 14, 1, (8), 10.1186/s13561-023-00475-2)

Okamoto S., Sata M., Rosenberg M., Nakagoshi N., Kamimura K., Komamura K., Kobayashi E., Sano J., Hirazawa Y., Okamura T., Iso H.

Health Economics Review 14 ( 1 ) 20 2024.12

ISSN 2191-1991

Correction to: Health Econ Rev 14, 8 (2024) Following the publication of the original article [1], the license copyright has been corrected to CC BY 3.0 IGO instead of Creative Commons Attribution 4.0 International License. The full correct copyright line should read as below: © World Health Organization 2024. Open Access This article is licensed under the terms of the Creative Commons Attribution 3.0 IGO License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the World Health Organization, provide a link to the Creative Commons licence and indicate if changes were made. The use of the World Health Organization’s name, and the use of the World Health Organization’s logo, shall be subject to a separate written licence agreement between the World Health Organization and the user and is not authorized as part of this CC-IGO licence. Note that the link provided below includes additional terms and conditions of the licence. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/3.0/igo/. Old Copyright Line: © World Health Organization 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. The original article [1] has been updated.

Access to Document (DOI)

New Insights Into the Relation Between Metabolic Dysfunction Associated Fatty Liver Disease and Cardiovascular Disease

Hirata A., Okamura T.

JACC: Asia (JACC: Asia) 3 ( 6 ) 922 - 924 2023

ISSN 2772-3747

Access to Document (DOI)

Correction: Determinants of double product: a cross-sectional study of urban residents in Japan (Environ Health Prev Med (2023), 28, 37, 10.1265/ehpm.23-00002)

Nakagoshi N., Kubo S., Nishida Y., Kuwabara K., Hirata A., Sata M., Higashiyama A., Kubota Y., Hirata T., Tatsumi Y., Kawamura K., Miyazaki J., Miyamatsu N., Sugiyama D., Miyamoto Y., Okamura T.

Environmental Health and Preventive Medicine (Environmental Health and Preventive Medicine) 28 74 2023

ISSN 1342078X

After the publication of this article [1], it was discovered that there was a typo in one sentence of the discussion. Therefore, we will correct it as follows. On line 47 of the discussion, it says “This is equivalent to playing tennis for approximately 10 min daily or running for about 7–8 min daily.” This is corrected to “This is equivalent to playing tennis for approximately 1 hour daily or running for about 40 min daily.” Published online: 5 December 2023 References 1. Nakagoshi N, Kubo S, Nishida Y, Kuwabara K, Hirata A, Sata M, et al. Determinants of double product: a cross-sectional study of urban residents in Japan. Environ Health Prev Med. 2023;28:37. https://doi.org/10.1265/ehpm.23-00002. Environmental Health and Preventive Medicine Environmental Health and Preventive Medicine (2023) 28:74 https://doi.org/10.1265/ehpm.23-00220.

Access to Document (DOI)

Serum modified high-density lipoprotein and risk of atherosclerotic cardiovascular disease in a Japanese community-based nested case-control study

Sata M., Kakino A., Hirata A., Iida M., Usami Y., Harada S., Fujita Y., Kohsaka S., Izawa Y., Sawano M., Oki K., Sugiyama D., Takahashi S., Takebayashi T., Sawamura T., Okamura T.

European Journal of Preventive Cardiology (European Journal of Preventive Cardiology) 29 ( 5 ) E193 - E195 2022.03

ISSN 20474873

Access to Document (DOI)

Erratum: Development of a cardiovascular disease risk prediction model using the suita study, a population-based prospective cohort study in Japan (Journal of Atherosclerosis and Thrombosis, (2020) 27, 11, (1160-1175), 10.5551/jat.48843)

Nakai M., Watanabe M., Kokubo Y., Nishimura K., Higashiyama A., Takegami M., Nakao Y.M., Okamura T., Miyamoto Y.

Journal of Atherosclerosis and Thrombosis (Journal of Atherosclerosis and Thrombosis) 28 ( 3 ) 2021

ISSN 13403478

Incorrect Since CVD risk increases with age, categories for age were based on 10-year intervals up to age 60 years and 5-year intervals thereafter. Diabetes mellitus (DM) is defined as having a fasting blood glucose level of ≥ 126 mg/dL, currently using anti-diabetic medication, or both. Cigarette smoking was dichotomized as current versus other. Low-density lipoprotein cholesterol (LDL-C) was calculated using the Friedewald equation . Non-HDL-C was calculated by subtracting HDL-C from TG. If the TG level was greater than 400 mg/dL, we set the value as missing (n =96). Correct Since CVD risk increases with age, categories for age were based on 10-year intervals up to age 60 years and 5-year intervals thereafter. Diabetes mellitus (DM) is defined as having a fasting blood glucose level of ≥ 126 mg/dL, currently using anti-diabetic medication, or both. Cigarette smoking was dichotomized as current versus other. Low-density lipoprotein cholesterol (LDL-C) was calculated using the Friedewald equation . Non-HDL-C was calculated by subtracting HDL-C from TC. If the TG level was greater than 400 mg/dL, we set the value as missing (n=96). 27) 27)

Access to Document (DOI)

Guidelines on the clinical evaluation of medicinal products for treatment of dyslipidemia

Yamashita S., Masuda D., Akishita M., Arai H., Asada Y., Dobashi K., Egashira K., Harada-Shiba M., Hirata K., Ishibashi S., Kajinami K., Kinoshita M., Kozaki K., Kuzuya M., Ogura M., Okamura T., Sato K., Shimano H., Tsukamoto K., Yokode M., Yokote K., Yoshida M.

Journal of Atherosclerosis and Thrombosis (Journal of Atherosclerosis and Thrombosis) 27 ( 11 ) 1246 - 1254 2020

ISSN 13403478

Access to Document (DOI)

Statin intolerance clinical guide 2018

Kajinami K., Tsukamoto K., Koba S., Inoue I., Yamakawa M., Suzuki S., Hamano T., Saito H., Saito Y., Masuda S., Nakayama T., Okamura T., Yamashita S., Kagawa T., Kaneyama J., Kuriyama A., Tanaka R., Hirata A.

Journal of Atherosclerosis and Thrombosis (Journal of Atherosclerosis and Thrombosis) 27 ( 4 ) 375 - 396 2020

ISSN 13403478

Access to Document (DOI)

日本における脂質と動脈硬化性疾患の関連-疫学研究のエビデンス-.

平田匠、岡村智教．

Medical Practice 36 ( 1 ) 40 - 44 2019

Article, review, commentary, editorial, etc. (scientific journal), Joint Work

脂質異常症のスクリーニングとリスク評価．

桑原和代、岡村智教．

臨床と研究 96 ( 1 ) 6 - 11 2019

Article, review, commentary, editorial, etc. (scientific journal), Joint Work

高HDL血症と心血管イベントに関する疫学研究からの知見-日常診療で高HDL血症をみつけたらどうするか．

岡村智教．

医学のあゆみ 268 ( 5 ) 415 - 419 2019

Article, review, commentary, editorial, etc. (scientific journal), Single Work

塩味味覚感度の低さは仮面高血圧に関連する：神戸研究

久保田芳美、若林一郎、岡村智教．

血圧 26 ( 5 ) 248 - 249 2019

Article, review, commentary, editorial, etc. (scientific journal), Joint Work

糖尿病と腎臓病の重症化予防事業-循環器疾患との関連を中心に-

岡村智教．

日本栄養士会雑誌 62 ( 3 ) 14 - 17 2019

Article, review, commentary, editorial, etc. (scientific journal), Single Work

動脈硬化性疾患予防ガイドラインの留意点と働き盛りの脳・心血管疾患の予防．

岡村智教

産業医学ジャーナル 42 ( 3 ) 69 - 74 2019

Article, review, commentary, editorial, etc. (scientific journal), Single Work

特定健診・特定保健指導からみた循環器疾患予防の現状と課題．

桑原和代、岡村智教．

公衆衛生 83 ( 5 ) 338 - 343 2019

Article, review, commentary, editorial, etc. (scientific journal), Joint Work

Carotid intima-media thickness and plaque in apparently healthy Japanese individuals with an estimated 10-year absolute risk of CAD death according to the Japan atherosclerosis society (JAS) guidelines 2012: The shiga epidemiological study of subclinical atherosclerosis (SESSA) (J Atheroseler Thromb, (2013) 20, (755-766), 10.5551/jat.17244)

Kadota A., Miura K., Okamura T., Fujiyoshi A., Ohkubo T., Kadowaki T., Takashima N., Hisamatsu T., Nakamura Y., Kasagi F., Maegawa H., Kashiwagi A., Ueshima H.

Journal of Atherosclerosis and Thrombosis (Journal of Atherosclerosis and Thrombosis) 26 ( 8 ) 746 - 746 2019

ISSN 13403478

© 2019, Japan Atherosclerosis Society. All rights reserved. Incorrect Methods Study Population Between 2006 and 2008, 2,381 Japanese men 40 to 79 years of age were randomly selected based on age strata from Kusatsu City, Japan and sent an invitation to participate in the baseline survey of the Shiga Epidemiological Study of Subclinical Atherosclerosis (SESSA). Of these men, 1,096 agreed to participate. The population of 40-to 79-year-old men in Kusatsu city was 25,394 in April 2005. Therefore, the extraction rate was 9.4% (2,381/25,394), and the participation rate in this survey was 46% (1,096/2,381) for men. Correct Methods Study Population Between 2006 and 2008, 2,379 Japanese men 40 to 79 years of age were randomly selected based on age strata from Kusatsu City, Japan and sent an invitation to participate in the baseline survey of the Shiga Epidemiological Study of Subclinical Atherosclerosis (SESSA). Of these men, 1,094 agreed to participate. The population of 40-to 79-year-old men in Kusatsu city was 25,394 in April 2005. Therefore, the extraction rate was 9.4% (2,379/25,394), and the participation rate in this survey was 46% (1,094/2,379) for men.

Access to Document (DOI)

The Japanese Society of Hypertension—Digest of plan for the future

Node K., Kishi T., Tanaka A., Itoh H., Rakugi H., Ohya Y., Miura K., Okamura T., Ishimitsu T., Ichihara A., Ito M., Ohishi M., Ohkubo T., Kai H., Kashihara N., Kario K., Saitoh S., Tsuchihashi T., Nakamura S., Nishiyama A., Hasebe N., Higaki J., Tamura K., Kawano Y., Yatabe T., Ito S.

Hypertension Research (Hypertension Research) 41 ( 12 ) 989 - 990 2018.12

ISSN 09169636

Access to Document (DOI)

Cardiometabolic index as a useful discriminator for the risk of increased arterial stiffness

Wakabayashi I., Marumo M., Kubota Y., Higashiyama A., Miyamoto Y., Okamura T.

Clinica Chimica Acta (Clinica Chimica Acta) 486 42 - 43 2018.11

ISSN 00098981

Access to Document (DOI)

Corrigendum to “Lipoprotein-associated phospholipase A2 is related to risk of subclinical atherosclerosis but is not supported by Mendelian randomization analysis in a general Japanese population.” [Atherosclerosis 246 (March 2016) 141–147](S0021915015302562)(10.1016/j.atherosclerosis.2015.12.027)

Ueshima H., Kadowaki T., Hisamatsu T., Fujiyoshi A., Miura K., Ohkubo T., Sekikawa A., Kadota A., Kadowaki S., Nakamura Y., Miyagawa N., Okamura T., Kita Y., Takashima N., Kashiwagi A., Maegawa H., Horie M., Yamamoto T., Kimura T., Kita T.

Atherosclerosis (Atherosclerosis) 278 336 - 336 2018.11

ISSN 00219150

© 2015 Elsevier B.V. The authors of the above paper have realized that an error has occurred in the number of eligible individuals selected and individuals who agreed to participate as below (page 142, 7th line of the paragraph immediately under “2.1. Study population”. (current) Of the 2994 eligible individuals selected, 1238 (1094 men) agreed to participate. (correct) Of the 2866 eligible individuals selected, 1236 (1094 men) agreed to participate. They assure that this error does not influence analyses, results, nor conclusions in the paper at all because all the analyses were conducted only for men, and therefore the number of study participants in the analyses is unchanged.

Access to Document (DOI)

Response to the letter entitled “Extremely high levels of high-density lipoprotein cholesterol and increased risk of cardiovascular mortality” by Dr Kawada

Hirata A., Okamura T.

Journal of Clinical Lipidology (Journal of Clinical Lipidology) 12 ( 6 ) 1551 - 1551 2018.11

ISSN 19332874

Access to Document (DOI)

Association between glycemic control and incident stroke ― Overview from an epidemiologic study

Hirata T., Okamura T.

Circulation Journal (Circulation Journal) 82 ( 6 ) 1499 - 1500 2018

ISSN 13469843

Access to Document (DOI)

Guidelines for diagnosis and treatment of familial hypercholesterolemia 2017

Harada-Shiba M., Arai H., Ishigaki Y., Ishibashi S., Okamura T., Ogura M., Dobashi K., Nohara A., Bujo H., Miyauchi K., Yamashita S., Yokote K.

Journal of Atherosclerosis and Thrombosis (Journal of Atherosclerosis and Thrombosis) 25 ( 8 ) 751 - 770 2018

ISSN 13403478

© 2018 Japan Atherosclerosis Society. Statement 1. Familial hypercholesterolemia (FH) is an autosomal hereditary disease with the 3 major clinical features of hyper-LDL-cholesterolemia, premature coronary artery disease and tendon and skin xanthomas. As there is a considerably high risk of coronary artery disease (CAD), in addition to early diagnosis and intensive treatment, family screening (cascade screening) is required (Recommendation level A) 2. For a diagnosis of FH, at least 2 of the following criteria should be satisfied: ① LDL-C ≥180 mg/dL, ② Tendon/skin xanthomas, ③ History of FH or premature CAD within 2nd degree blood relatives (Recommendation level A) 3. Intensive lipid-lowering therapy is necessary for the treatment of FH. First-line drug should be statins. (Rec-ommendation level A, Evidence level 3) 4. Screening for CAD as well as asymptomatic atherosclerosis should be conducted periodically in FH patients. (Recommendation level A) 5. For homozygous FH, consider LDL apheresis and treatment with PCSK9 inhibitors or MTP inhibitors. (Rec-ommendation level A) 6. For severe forms of heterozygous FH who have resistant to drug therapy, consider PCSK9 inhibitors and LDL apheresis. (Recommendation level A) 7. Refer FH homozygotes as well as heterozygotes who are resistant to drug therapy, who are children or are pregnant or have the desire to bear children to a specialist. (Recommendation level A).

Access to Document (DOI)

飲酒と脳・心血管疾患の関連－わが国疫学調査から－．

岡村智教、杉山大典．

Fronties in Alcoholism 6 ( 1 ) 12 - 18 2018

Article, review, commentary, editorial, etc. (scientific journal), Single Work

動脈硬化性疾患に対する包括的リスク管理．

岡村智教．

Mebio 35 ( 3 ) 45 - 51 2018

Article, review, commentary, editorial, etc. (scientific journal), Single Work

飲酒と循環器疾患．

久保智佐美、岡村智教．

循環器内科 83 ( 4 ) 363 - 370 2018

Article, review, commentary, editorial, etc. (scientific journal), Joint Work

脂質異常症と冠動脈疾患-わが国の疫学研究から．

平田あや、岡村智教．

Heart View 22 ( 7 ) 612 - 618 2018

Article, review, commentary, editorial, etc. (scientific journal), Joint Work

循環器疾患対策の進捗状況と今後の課題．

岡村智教．

健康づくり 482 12 - 15 2018

Article, review, commentary, editorial, etc. (scientific journal), Single Work

わが国における血清コレステロール値および脂質異常症の時代的推移．

佐田みずき、岡村智教．

日循予防誌 53 ( 3 ) 220 - 226 2018

Joint Work

動脈硬化性疾患の絶対リスクと脂質管理目標値．

岡村智教．

日本医師会雑誌 147 ( 5 ) 970 - 974 2018

Article, review, commentary, editorial, etc. (scientific journal), Single Work

国内外の動脈硬化性疾患ガイドラインからみた脂質異常症の管理．

岡村智教．

The Lipid 29 ( 4 ) 419 - 425 2018

Article, review, commentary, editorial, etc. (scientific journal), Single Work

発症予測と絶対リスク．

平田あや、岡村智教．

CURRRENT THERAPY 36 ( 11 ) 1062 - 1067 2018

Article, review, commentary, editorial, etc. (scientific journal), Joint Work

冠動脈疾患発症予防のための絶対リスクの評価．

岡村智教．

The Lipid 29 ( 1 ) 27 - 33 2018

Article, review, commentary, editorial, etc. (scientific journal), Single Work

　 Previous page - Next page 　